Degradation and clearance of methotrexate in children with osteosarcoma receiving high-dose infusion
- PMID: 308151
- DOI: 10.1002/mpo.2950040305
Degradation and clearance of methotrexate in children with osteosarcoma receiving high-dose infusion
Abstract
Plasma methotrexate (MTX) concentrations were quantitated in 34 patients after 127 high-dose (35--350 mg/kg) infusions with citrovorum factor rescue. Significant linear correlations have been obtained between methotrexate dosage and concentrations in plasma at 6 and 24 hours after the initiation of the therapy. However, similar trends have not been observed when 48- and 72-hour samples were analyzed. Clinical toxicity was not serious when the methotrexate level in plasma was less than 4.5 X 10(-6) M at 48 hours after the start of a six-hour infusion in children. A minimal four-hour steady-state methotrexate plasma level can be maintained during a six-hour infusion. Children excrete methotrexate at a faster rate than adults; the half-life of MTX during the first phase of plasma clearance curve is one hour shorter in children. Urinary analyses have indicated that substantial methotrexate is metabolized. The chemical nature of these components has not been identified. Further, the urinary metabolic profiles varied among patients.
Similar articles
-
Clinical pharmacokinetics of methotrexate in children.Clin Pharmacokinet. 1984 Jul-Aug;9(4):335-48. doi: 10.2165/00003088-198409040-00003. Clin Pharmacokinet. 1984. PMID: 6380871 Review.
-
Age-related pharmacokinetics of high-dose methotrexate in patients with osteosarcoma.Cancer Treat Rep. 1979 Mar;63(3):405-10. Cancer Treat Rep. 1979. PMID: 284845
-
Essential laboratory determinations for monitoring high-dose methotrexate treatment with citrovorum factor rescue.Pediatr Pharmacol (New York). 1983;3(3-4):157-65. Pediatr Pharmacol (New York). 1983. PMID: 6610851
-
High-dose methotrexate with a safe rescue program.Oncology. 1981;38(5):262-4. doi: 10.1159/000225566. Oncology. 1981. PMID: 6973732
-
Antineoplastic agents: high-dose methotrexate and citrovorum factor rescue.Ther Drug Monit. 1980;2(2):177-85. Ther Drug Monit. 1980. PMID: 6762711 Review.
Cited by
-
[Multidrug chemotherapy of osteogenic sarcoma (author's transl)].Blut. 1979 Oct;39(4):293-300. doi: 10.1007/BF01013224. Blut. 1979. PMID: 291443 German.
-
Pharmacokinetic study of indicine N-oxide in pediatric cancer patients.Cancer Chemother Pharmacol. 1982 Dec;10(1):43-6. doi: 10.1007/BF00257237. Cancer Chemother Pharmacol. 1982. PMID: 7160044
-
Pharmacokinetics of low-dose methotrexate in children receiving maintenance therapy for acute lymphoblastic leukaemia.Cancer Chemother Pharmacol. 1982 Dec;10(1):36-9. doi: 10.1007/BF00257235. Cancer Chemother Pharmacol. 1982. PMID: 6961972
-
The Current and Future Therapies for Human Osteosarcoma.Curr Cancer Ther Rev. 2013 Feb;9(1):55-77. doi: 10.2174/1573394711309010006. Curr Cancer Ther Rev. 2013. PMID: 26834515 Free PMC article.
-
Clinical pharmacokinetics of methotrexate in children.Clin Pharmacokinet. 1984 Jul-Aug;9(4):335-48. doi: 10.2165/00003088-198409040-00003. Clin Pharmacokinet. 1984. PMID: 6380871 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources